The past three years of M&A activity in Revenue Cycle Management (RCM) and Healthcare Information Technology (HCIT) have been incredibly busy, with more than $150 billion changing hands in 700 transactions. As owners, investors and senior executives of RCM and HCIT companies consider their M&A options, they often have questions about how to determine valuation multiples for their companies. What, how, and when buyers pay for a company is directly tied to what they perceive to be the potential return on the investment, the time horizon for that return, and the risk involved in realizing that return. Greenberg Advisors’ concise guide outlines some of the most common considerations in RCM and HCIT transactions.
In this guide, you’ll learn:
- Some of the most important factors in determining a company’s valuation
- Valuation ranges for RCM and HCIT companies
- The benefits of different forms of consideration in M&A deals
Sponsored by:
